8,659 Shares in DexCom, Inc. $DXCM Bought by USA Financial Formulas

USA Financial Formulas acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, HoldingsChannel reports. The institutional investor acquired 8,659 shares of the medical device company’s stock, valued at approximately $747,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Reflection Asset Management bought a new stake in shares of DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the 1st quarter valued at $25,000. Elevation Wealth Partners LLC lifted its stake in shares of DexCom by 61.0% during the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after buying an additional 152 shares in the last quarter. GK Wealth Management LLC bought a new position in DexCom in the 3rd quarter worth $35,000. Finally, Wellington Grp LLC boosted its holdings in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of analyst reports. Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. UBS Group set a $96.00 price target on DexCom and gave the company a “buy” rating in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective on the stock. Benchmark upped their price objective on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup reaffirmed a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $92.43.

DexCom Trading Down 1.9%

Shares of DXCM opened at $86.04 on Friday. The firm has a market cap of $32.47 billion, a P/E ratio of 34.01, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a 50 day simple moving average of $87.61 and a two-hundred day simple moving average of $75.86.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Nicholas Augustinos sold 6,539 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the transaction, the director directly owned 29,293 shares of the company’s stock, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction on Monday, September 28th. The shares were sold at an average price of $86.15, for a total transaction of $220,974.75. Following the completion of the sale, the executive vice president owned 123,478 shares in the company, valued at approximately $10,637,629.70. This represents a 2.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,313 shares of company stock valued at $3,945,875 in the last quarter. Company insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.